Guanfacine for PONV and Pain After Sinus Surgery

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Postoperative nausea and vomiting (PONV) and pain are the most common causes of Post Anesthesia Care Unit (PACU) discharge delay, with untreated PONV occurring in 20-30% of post-surgical patients. The effect of guanfacine (GF) administration on pain and nausea scores will be assessed with two groups. One group will receive 1 mg of GF to take orally and the other group will receive a similar appearing placebo (containing no drug) to take orally.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Guanfacine

Criteria

Inclusion Criteria:

• VUMC patients undergoing sinus surgery in MCE OR

Exclusion Criteria:

• Inability to read and freely consent

• Patients who take alpha-2 agonists routinely (guanfacine, clonidine, tizanidine)

• Patients undergoing sinus surgery planned for greater than 3 hours

• Patients with significant pre-existing pain, on chronic pain (opioid, methadone) therapy, severe fibromyalgia or other pre-existing pain condition in any body part

• Patients with preoperative nausea/vomiting at baseline.

• Pregnant or lactating women